Ignite Creation Date:
2024-05-05 @ 11:47 AM
Last Modification Date:
2024-10-26 @ 9:13 AM
Study NCT ID:
NCT00132756
Status:
TERMINATED
Last Update Posted:
2006-11-08
First Post:
2005-08-18
Brief Title:
Liposomal Doxorubicin and Estramustine Phosphate Study in Taxane Resistant Hormone Refractory Advanced Prostate Cancer
Sponsor:
Morton Plant Mease Health Care
Organization:
Morton Plant Mease Health Care
Study Overview
Official Title:
Liposomal Doxorubicin and Estramustine Phosphate A Phase II Study in Taxane Resistant Hormone Refractory Advanced Prostate Cancer
Status:
TERMINATED
Status Verified Date:
2006-11
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this research study is to test the safety tolerability and effectiveness of the drug combination of Doxil doxorubicin and estramustine when used to treat prostate cancer that is resistant to hormones and to a chemotherapy type called taxanes
The primary hypothesis is to reduce the measurable disease or prostate-specific antigen PSA level by at least 50 from baseline
The primary hypothesis is to reduce the measurable disease or prostate-specific antigen PSA level by at least 50 from baseline
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None